Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 4/2020

Open Access 01-08-2020 | Cervical Cancer | Research Article

Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET

Authors: SV Hartimath, O. Draghiciu, T Daemen, H.W. Nijman, A. van Waarde, R.A.J.O. Dierckx, E.F.J. de Vries

Published in: Molecular Imaging and Biology | Issue 4/2020

Login to get access

Abstract

Purpose

Chemokine CXCL12 and its receptor CXCR4 are constitutively overexpressed in human cancers. The CXCL12-CXCR4 signaling axis plays an important role in tumor progression and metastasis, but also in treatment-induced recruitment of CXCR4-expressing cytotoxic immune cells. Here, we aimed to demonstrate the feasibility of N-[11C]methyl-AMD3465 positron emission tomography (PET) to monitor changes in CXCR4 density in tumors after single-fraction local radiotherapy or in combination with immunization.

Procedure

TC-1 cells expressing human papillomavirus antigens E6 and E7 were inoculated into the C57BL/6 mice subcutaneously. Two weeks after tumor cell inoculation, mice were irradiated with a single-fraction 14-Gy dose of X-ray. One group of irradiated mice was immunized with an alpha-viral vector vaccine, SFVeE6,7, and another group received daily injections of the CXCR4 antagonist AMD3100 (3 mg/kg -intraperitoneal (i.p.)). Seven days after irradiation, all animals underwent N-[11C]methyl-AMD3465 PET.

Results

PET imaging showed N-[11C]methyl-AMD3465 uptake in the tumor of single-fraction irradiated mice was nearly 2.5-fold higher than in sham-irradiated tumors (1.07 ± 0.31 %ID/g vs. 0.42 ± 0.05 % ID/g, p < 0.01). The tumor uptake was further increased by 4-fold (1.73 ± 0.17 % ID/g vs 0.42 ± 0.05 % ID/g, p < 0.01) in mice treated with single-fraction radiotherapy in combination with SFVeE6,7 immunization. Administration of AMD3100 caused a 4.5-fold reduction in the tracer uptake in the tumor of irradiated animals (0.24 ± 0.1 % ID/g, p < 0.001), suggesting that tracer uptake is indeed due to CXCR4-mediated chemotaxis.

Conclusion

This study demonstrates the feasibility of N-[11C]methyl-AMD3465 PET imaging to monitor treatment-induced changes in the density of CXCR4 receptors in tumors and justifies further evaluation of CXCR4 as a potential imaging biomarker for evaluation of anti-tumor therapies.
Literature
1.
Fran B (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14:171–117CrossRef
2.
Kodama J, Hasengaowa KT et al (2007) Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol 18:70–76CrossRef
3.
Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121–127CrossRef
4.
5.
Braunersreuther V, Mach F, Steffens S (2007) The specific role of chemokines in atherosclerosis. Thromb Haemostasis. 97:714–721CrossRef
6.
Ara T, Tokoyoda K, Sugiyama T et al (2003) Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity 19:257–267CrossRef
7.
Rostene W, Kitabgi P, Parsadaniantz SM (2007) Chemokines: a new class of neuromodulator? Nat Rev Neurosci 8:895–903CrossRef
8.
Kukreja P, Abdel-Mageed A, Mondal D et al (2005) Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1α (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signalling pathway-dependent NF-kappaB activation. Cancer Res 65:9891–9898CrossRef
9.
Teicher BA, Fricker SP (2010) CXCL12 (SDF-1)/CXCR4 Pathway in Cancer. Clin Cancer Res 16:2927–2931CrossRef
10.
Muller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56CrossRef
11.
Ma Q (1998) Impaired B lymphopoiesis, myelopoiesis and derailed cerebellar neuronal migration in CXCR4 and SDF-1 deficient mice. Proc Natl Acad Sci USA 95:9448–9453CrossRef
12.
Aiuti A, Webb IJ, Bleul C et al (1997) The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 185:111–120CrossRef
13.
Sison EAR, McIntyre E, Magoon D, Brown P (2013) Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res 11:1004–1016CrossRef
14.
Hirota K, Semenza GL (2006) Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol 59:15–26CrossRef
15.
Hartmann TN, Burger JA, Glodek A et al (2005) CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24:4462–4471CrossRef
16.
Willers H, Azzoli CG, Santivasi WL, Xia F (2013) Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J 19:200–207CrossRef
17.
Li J, Jiang K, Qiu X et al (2013) Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer. BMB Reports 47:33–38CrossRef
18.
Tamamura H, Hori A, Kanzaki N et al (2003) T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Letters 550:79–83CrossRef
19.
Liang Z, Wu T, Lou H et al (2004) Inhibition of Breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 64:4302–4308CrossRef
20.
Redjal N, Chan JA, Segal RA, Kung AL (2006) CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 12:6765–6771CrossRef
21.
Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, Alsawafi Y, Mourskaia AA, Siegel PM, Salvucci O, Basik M (2011) CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 129:225–232CrossRef
22.
Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, Kliphuis NM, Huls G, de Vries EG, de Jong IJ, Walenkamp AM (2012) CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 14:709–718CrossRef
23.
Lee C, Kakinuma T, Wang J et al (2006) Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol Cancer Ther 5:2592–2599CrossRef
24.
Mitchell B, Leone D, Feller JK et al (2014) Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status. Melanoma Res. 24
25.
Feig C, Jones JO, Kraman M et al (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 110:20212–20217CrossRef
26.
Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG (2015) CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice. Hepatology 61:1591–1602CrossRef
27.
Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611–618CrossRef
28.
Sutmuller RPM, van Duivenvoorde LM, van Elsas A et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 194:8CrossRef
29.
Hartimath SV, van Waarde A, Dierckx RAJO, de Vries EFJ (2014) Evaluation of N-[11C]Methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model. Mol Pharmaceutics 11:3810–3817CrossRef
30.
Hartimath SV, Khayum MA, van Waarde A et al (2017) N-[11C]Methyl-AMD3465 PET as a tool for in vivo measurement of chemokine receptor 4 (CXCR4) occupancy by therapeutic drugs. Mol Imaging Biol 19:570–577CrossRef
31.
Hartimath SV, Domanska UM, Walenkamp AME, Rudi AJOD, de Vries EF (2013) [99mTc]O2-AMD3100 as a SPECT tracer for CXCR4 receptor imaging. Nucl Med Biol 40:507–517CrossRef
32.
Draghiciu O, Boerma A, Hoogeboom BN et al (2015) A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology 4:e1029699CrossRef
33.
Draghiciu O, Walczak M, Hoogeboom BN et al (2014) Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int J Cancer 134:859–872CrossRef
34.
Daemen T, Riezebos-Brilman A, Regts J, Dontje B, van der Zee A, Wilschut J (2004) Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 9:733–742PubMed
35.
Hung C, Wu TC, Monie A, Roden R (2008) Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev 222:43–69CrossRef
36.
Vukovic V, Haugland HK, Nicklee T et al (2001) Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 61:7394–7398PubMed
37.
38.
Chatterjee S, Azad BB, Nimmagadda S (2014) The intricate role of CXCR4 in cancer. Adv Cancer Res 124:31–82CrossRef
39.
Metadata
Title
Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET
Authors
SV Hartimath
O. Draghiciu
T Daemen
H.W. Nijman
A. van Waarde
R.A.J.O. Dierckx
E.F.J. de Vries
Publication date
01-08-2020
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 4/2020
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-019-01447-x

Other articles of this Issue 4/2020

Molecular Imaging and Biology 4/2020 Go to the issue

Research Article

Monitoring CD8a+ T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [64Cu]NOTA-CD8a PET Imaging

Research Article

Nanoparticle Formulation of Indocyanine Green Improves Image-Guided Surgery in a Murine Model of Breast Cancer

Brief Article

Type of Anaesthetic Influences [11C]MDL100,907 Binding to 5HT2A Receptors in Porcine Brain

Research Article

Body Mass Index and Age Effects on Brain 11β-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study

Research Article

A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry

Research Article

Magnetic Particle Imaging of Macrophages Associated with Cancer: Filling the Voids Left by Iron-Based Magnetic Resonance Imaging